Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Adrenocortical carcinoma (ACC) is a rare disease caused by cancerous growth in the adrenal cortex, which is the outer layer of the adrenal glands. The adrenal glands lie on top of the kidneys. They play a major role in the endocrine system, which is the system that produces and regulates hormones. The causes of primary adrenocortical carcinoma are unknown. However adrenocortical carcinoma can also be secondary cancer. A secondary cancer is what happens when another form of cancer spreads to the adrenal glands. Adrenocortical carcinoma can occur at any age, but there is a bimodal distribution with a first peak at childhood between 1–6 years old and the second peak in the fourth to the fifth decade of life. During the past decade, collaborative efforts have been made to improve the ACC treatment.
Some of the key factors that are driving the adrenocortical carcinoma treatment market are increasing the prevalence of cancer, rising government involvement, increasing funding from various government and non-government organizations. Also, ethical acceptance of adrenocortical carcinoma treatment and high unmet needs in some regions are driving the adrenocortical carcinoma treatment market. However, less awareness and high cost involved in treatment are restraining the global adrenocortical carcinoma treatment market. Also, the introduction of generic drugs in some countries is restraining the growth of adrenocortical carcinoma treatment market. Also, despite the high cost involved in R&D, pharmaceutical companies are showing increased interest in this field. This is expected to offer good potential for adrenocortical carcinoma treatment market.
Market Analysis and Insights: Global Adrenocortical Carcinoma Treatment Market
The global Adrenocortical Carcinoma Treatment market size is projected to reach US$ 545.6 million by 2026, from US$ 537 million in 2020, at a CAGR of 1.5%% during 2021-2026.
Global Adrenocortical Carcinoma Treatment Scope and Market Size
Adrenocortical Carcinoma Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Adrenocortical Carcinoma Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
ArQule
EnGeneIC
Exelixis
Merck
Millendo Therapeutics
Orphagen Pharmaceuticals
...
Localized Adrenocortical Carcinoma
Metastatic Adrenocortical Carcinoma
Hospitals
Ambulatory Surgical Centers
Clinics
Cancer Research Institutes
North America
Europe
China
Japan
Southeast Asia
India
Some of the key factors that are driving the adrenocortical carcinoma treatment market are increasing the prevalence of cancer, rising government involvement, increasing funding from various government and non-government organizations. Also, ethical acceptance of adrenocortical carcinoma treatment and high unmet needs in some regions are driving the adrenocortical carcinoma treatment market. However, less awareness and high cost involved in treatment are restraining the global adrenocortical carcinoma treatment market. Also, the introduction of generic drugs in some countries is restraining the growth of adrenocortical carcinoma treatment market. Also, despite the high cost involved in R&D, pharmaceutical companies are showing increased interest in this field. This is expected to offer good potential for adrenocortical carcinoma treatment market.
Market Analysis and Insights: Global Adrenocortical Carcinoma Treatment Market
The global Adrenocortical Carcinoma Treatment market size is projected to reach US$ 545.6 million by 2026, from US$ 537 million in 2020, at a CAGR of 1.5%% during 2021-2026.
Global Adrenocortical Carcinoma Treatment Scope and Market Size
Adrenocortical Carcinoma Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Adrenocortical Carcinoma Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
ArQule
EnGeneIC
Exelixis
Merck
Millendo Therapeutics
Orphagen Pharmaceuticals
...
Market segment by Type, the product can be split into
Localized Adrenocortical Carcinoma
Metastatic Adrenocortical Carcinoma
Market segment by Application, split into
Hospitals
Ambulatory Surgical Centers
Clinics
Cancer Research Institutes
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
